Index

A

Acute leukemia (AL)
- acute myeloid leukemia, 35–39
- B-acute lymphoblastic leukemia, 25–27
- blastic plasmacytoid dendritic cell tumor, 41
- clinical features, 22
- diagnosis, 22–23
- Down syndrome, 40–41
- evaluation of (*see* Pediatric acute leukemia, evaluation)
- genetic abnormalities, 25–27
- hereditary disorders with predisposition, 41–42
- immunophenotype, 23–24
- morphology, 23, 24
- numerical chromosomal aberrations, 28
- precursor T-cell leukemia/lymphoma, 34–35
- prognosis, 25
- risk-stratification, 22
- structural aberrations
  - t(4;11)(q21;q23)/AFF1/MLL (AF4/MLL), 31, 32
  - t(9;22)(q34;q11)/BCR-ABL1 translocation/Philadelphia chromosome, 28–31
  - t(12;21)(q21;q22)/ETV6-RUNX1 (TEL/AML1), 33
  - t(8;14)(q24;q32)/MYC-IGH, 33–34
  - t(1;19)(q23;p13)/TCF3-PBX1 (E2/PBX1), 32–33
- therapy-related myeloid neoplasms (t-MN), 40

Acute lymphoblastic leukemia (ALL), 21, 22. *See also* Acute leukemia (AL)
- Down syndrome, 92
- GWAS, 13
- *vs.* lymphoblastic lymphomas, 112
- microarray profiling, 63–66
- T cell leukemia, 62
- with triple trisomies, 29

Acute megakaryoblastic leukemia (AMkL), 36, 40, 41, 89

Acute myeloid leukemia (AML), 84
- Down syndrome, 89–92
- genetic aberrations, 35–39

Acute promyelocytic leukemia (APL), 24

Adenomatous polyposis coli *(APC)* gene mutation, 202, 247

Affymetrix assay, 11

Aggressive NK-cell leukemia, 113

AL. *See* Acute leukemia (AL)

ALCL. *See* Anaplastic large cell lymphoma (ALCL)

ALL. *See* Acute lymphoblastic leukemia (ALL)

Alveolar rhabdomyosarcoma, 183–185

Anaplastic large cell lymphoma (ALCL), 108–111
- anaplastic lymphoma kinase (ALK) translocation
  - diffuse cytoplasmic and nuclear staining, 110
  - FISH, 111
- diagnosis, 111–112
- hallmark cells, 109
- immunohistochemistry, CD30 positive cells, 110
- sinusoidal growth pattern, 109

Anaplastic/large cell medulloblastomas, 127, 131

Anaplastic lymphoma kinase (ALK), 109, 110, 174
- gene rearrangement, inflammatory myofibroblastic tumor, 211–213

A.C. Mackinnon Jr. (ed.), *Pediatric Neoplasia: Advances in Molecular Pathology and Translational Medicine*, Molecular and Translational Medicine,
DOI 10.1007/978-1-62703-116-5, © Springer Science+Business Media New York 2012

Apoptosis mechanism abnormalities, in osteosarcoma
bax and cytochrome C, 150
livin and survivin, 150
Array comparative genomic hybridization (aCGH), 8, 88
Astrocytomas
description, 132
infiltrating astrocytomas, 135–137
pilocytic astrocytomas, 134–135
preexisting neurons, entrapment of, 133
Rosenthal fibers, 132
WHO classification, 132

B
Bacterial artificial chromosomes (BACs), 4
B-acute lymphoblastic leukemia (B-ALL), 25–27
BARD1 gene, 13
Bax protein, 150
Beckwith–Wiedemann syndrome (BWS), 226, 228
Bednar tumor, 206, 207
Billings, S.D., 207
BL. *See* Burkitt lymphoma (BL)
Blastic plasmacytoid dendritic cell tumor (BPDCN), 41
Bloom syndrome, 86
Bone marrow failure syndromes, MDS/AML, 84
Bone tumor
cartilage tumors
chondroblastoma, 157–158
chondromyxoid fibroma, 160–161
mesenchymal chondrosarcoma, 162–163
osteochondroma, 154–156
subungual exostosis, 158–159
incidence, 141
osteogenic tumors
osteoblastoma, 144–145
osteoid osteoma, 142–145
osteosarcoma, 145–148
Boveri, T., 2, 16
BRAF, 134, 135
Breakpoint cluster region gene *(BCR)* gene, 3, 28
Burkitt lymphoma (BL)
vs. diffuse large B-cell lymphoma, 102–104
EBER, in-situ hybridization, 105, 113
epidemiologic variants, 102
FISH, 103, 111
IGH gene, 103
immunohistochemistry, 105, 110
morphological and immunophenotypic features, 106
MYC translocation, 103
touch imprint (Giemsa), 104

C
Cadherin-associated protein beta (CTNNB1), 230
cAMP-responsive element-binding protein 3-like protein 2 *(CREB3L2)* gene, 209
Cancer stem cell (CSC) and hepatoblastoma, 251–252
Cario, S., 247, 251
Cartilage tumors
chondroblastoma
carbonic anhydrase-related protein X (CA-RP X), 158
chicken-wire calcification, 157
clinicopathological characteristics, 157
molecular pathology, 158
proliferating-cell nuclear antigen (PCNA), 158
steroid 5-alpha-reductase 1 *(SRD5A1)*, 158
chondromyxoid fibroma
clinicopathological characteristics, 160–161
molecular pathology, 161
mesenchymal chondrosarcoma
clinicopathological characteristics, 162–163
molecular pathology, 163
small blue round cell tumors, 162
osteochondroma
chondrosarcomas, 155
clinicopathological characteristics, 154–157
contiguous gene-deletion syndrome, 155–156
exophytic growth and hypocellular cartilaginous cap, 155
exostosin, 156
molecular pathology, 156
near-haploidy, 156
sporadic solitary osteochondromas, 156
subungual exostosis
clinicopathological characteristics, 158–159
fibrocartilaginous areas, 159
molecular pathology, 160
t(X;6), 160

β-Catenin
Gardner fibroma, mutations, 202
mutations, 247, 248
nuclear expression, in desmoid-type fibromatosis, 203, 204
Cell cycle regulation abnormalities, in osteosarcoma, 148
Central nervous system (CNS) tumors
astroctyomas, 132–137 (*see also* Astrocytomas)
issues, 126
medulloblastomas, 126–132 (*see also* Medulloblastomas)
Childhood lymphoma. *See* Lymphoma
Chondroblastoma, 157–158
Chondromyxoid fibroma, 160–161
Chronic myelogenous leukemia (CML), 75, 81
Classical Hodgkin lymphoma (cHL), 108
Clear cell sarcoma of kidney (CCSK), 223, 225, 234, 238
CML. *See* Chronic myelogenous leukemia (CML)
c-Myc abnormalities, in osteosarcoma, 151
Coffin, C.M., 201, 210
COL12A1 gene, 160, 161
Colony forming units-granulocytic, monocytic (CFU-GM), hematopoietic growth factor dose-response curves for, 77
Comparative genomic hybridization (CGH), 7–9, 57–59, 87–89
Congenital fibrosarcoma, 199, 200
Congenital mesoblastic nephroma (CMN), 223, 225, 237–239
Conventional G-banded karyotyping, 53–55
Crick, F., 6
Cyclin-dependent kinase inhibitor 2A *(CDKN2A)*, 149
Cytochrome c protein, 150

D
DEFECT-11 (Potocki-Shaffer) syndrome, 156
Dermatofibrosarcoma protuberans (DFSP), 205–207
Desmoid-type fibromatosis
β-catenin nuclear expression, 203, 204
histologic features, 202, 203
matrix metalloproteinase-7 (MMP-7), 204
Desmoplastic small round cell tumor (DSRCT), 238
epidermal growth factor receptor (EGFR), 182
equilibrative nucleoside transporter 4 gene (ENT4), 182
EWS-related translocation, 181–182
histological features, 180
immunohistochemistry, 180–181
platelet derived growth factor alpha (PDGFA), 182
translocation, 181–182
WT1 nuclear expression, 181
Diffuse large B-cell lymphoma (DLBCL), 9, 104–107
Down syndrome (DS)
acute leukemia, 40–41
transient myeloproliferation and acute leukemia, 89–92
DSRCT. *See* Desmoplastic small round cell tumor (DSRCT)

E
Eggert, A., 175
Embryonal rhabdomyosarcoma, 183
Enzinger, F.M., 183
Ephithelial growth factor 2 (ErbB2) abnormalities, in osteosarcoma, 152
Epigenomics, 14
Epstein–Barr virus (EBV), 114
E26 transformation-specific *(ETS)* gene, 178–179
Evans, W., 13
Ewing sarcoma
alternative translocations, 178–179
CD99 immunostaining, 176, 177
cytogenetic abnormalities, 179
FISH analysis, 176
Fli-1 immunostaining, 177
pathological diagnosis, 176
Ewing sarcoma breakpoint region 1 *(EWSR1)* gene, 178
Exostosis. *See* Osteochondroma
Extranodal NK/T cell lymphoma, nasal type, 113

F
Fanconi anemia, 83, 86, 87
Fernandez Navarro, J.M., 227
FLT3 mutations, acute myeloid leukemia, 35–36
Fluorescence in situ hybridization (FISH)
for anaplastic lymphoma kinase *(ALK)* gene, 109, 212
Burkitt lymphoma, 102–104
centromeric probes, 56, 57
vs. conventional cytogenetics, 56
dual-color dual-fusion probe, 56, 57

Fluorescence in situ hybridization (FISH) (*cont.*)
Ewing sarcoma/PNET, 176, 178
genome-wide analyses, 6–7
limitations, 57
locus-specific probes, 56, 57
myelodysplasia, 85, 86
Follicular and marginal zone lymphomas, 114
Folpe, A.L., 207
Fos/Jun abnormalities, in osteosarcoma, 151–152
FOXO1 gene, 184, 186
French–American–British (FAB) classification of acute leukemia, 23, 24
Fused in sarcoma *(FUS)* gene, 209

G
Gall, J.G., 6
Gardner fibroma, 201–202
Gardner syndrome, 201
GATA1 mutations, 40, 91, 92
G-banded karyotyping, pediatric acute leukemia evaluation, 53–54
GBMs, 135, 136
Gene expression profiling (GEP), 9
Genome wide association studies (GWAS), 11
Genome-wide strategies
cytogenetics, 7
fluorescence in-situ hybridization (FISH), 6
genomics, 1
karyotyping, 5–6
limitations, 15
microarray technologies
comparative genomic hybridization, 7–9
epigenomics, 14
expression profiling, 9–10
hybridization, 7
microRNAs, 14
proteomics, 15
SNP arrays, 11
molecular diagnostics, 3
post-genome era, 1
pre-genome era, history of
chromosomal abnormality, 2
daughter cells, chromosome distribution, 2
hereditary and sporadic forms, in retinoblastoma, 3
mutations, 2, 3
risk-adapted therapy, 4
translocation, BCR-ABL tyrosine kinase, 3
Gerald, W.L., 179
Giant cell fibroblastoma, 205–207
Glioblastomas, 135, 136
Gorlin's syndrome, 129
Grosveld, G., 3
GWAS. *See* Genome wide association studies (GWAS)

H
HapMap project, 5
Hartmann, W., 249
Hattinger, C.M., 179
Heat shock proteins (HSP), in osteosarcoma, 154
Hedgehog signaling pathway, hepatoblastoma, 250
Hepatoblastoma, biology of
and cancer stem cell (CSC), 251–252
cell of origin, 252
chromosomal abnormalities, 244
pathology and genetics, 243–244
profiling, 250–251
prognosis, 244
signaling pathways
embryonal tumors, 244
genes, epigenetic abnormalities and micro RNAs, 245–246
hepatocyte growth factor/cMET signaling, 249
IGF signaling pathway (IGF/PI3K/AKT pathway), 248–249
Notch, 250
PI3K/AKT pathway, 249
Sonic Hedgehog, 250
Wnt pathway, 247–248
therapy, 243, 244
Hepatocellular carcinoma (HCC), 251, 252
Hepatocyte growth factor/cMET signaling, hepatoblastoma, 249
Hepatosplenic gamma-delta T-cell lymphoma, 113
High-grade gliomas (HGG), 132
High hyperdiploidy (HeH) cells, 28
HIPK2, pilocytic astrocytomas, 135
Hodgkin lymphoma (HL)
classical (cHL), 114
diagnosis, 115–117
nodular lymphocyte predominant HL (NLPHL), 114–115
Reed–Sternberg cells, 116
types of, 114
Honda, S., 249
Human Genome Project, 4, 5
Hungerford, D., 2
Hyalinizing spindle cell tumor with giant rosettes (HSTGR), 207, 208

I
IDH mutations, infiltrating astrocytomas, 136
Imatinib, 3
Immunodeficiency associated lymphoroliferative disorders, 102
Immunoglobulin heavy chain gene *(IGH)* gene, 103
  rearrangement, 62–63
Immunohistochemistry
  anaplastic large cell lymphoma, CD30 positive cells, 108–109
  Burkitt lymphoma, 102–104
Immunophenotype, acute leukemia, 23–24
Infantile/congenital fibrosarcoma, 199–201
Infiltrating astrocytomas
  glioblastomas, 135, 136
  IDH mutations, 136
  MGMT, 136
  molecular alterations, comparison of, 136
  PDGFRA, 135
Inflammatory myofibroblastic tumor (IMT)
  anaplastic lymphoma kinase *(ALK)* gene rearrangement, 211–213
  with extensive stromal hyalinization, 210
  histologic subtypes, 209–210
  karyotype, chromosome 2 inversion, 211
Insulin-like growth factor (IGF) signaling pathway (IGF/PI3K/AKT pathway), hepatoblastoma, 248–249
International System for Human Cytogenetics Nomenclature (ISCN), 54

J
Janoueix-Lerosey, I., 173
Juvenile myelomonocytic leukemia (JMML)
  diagnosis of
    criteria for, 79
    culture assays, 80
    molecular analyses, 80
    peripheral blood and BM morphology, 79–80
  molecular pathogenesis
    CFU-GM, hematopoietic growth factor dose-response curves for, 77
    genetic pathways in, 78
    neurofibromatosis type 1 (NF1), 76
    Noonan syndrome, 76, 77
    RAS signaling pathway, 76
Juvenile pilocytic astrocytomas (JPAs), 9

K
Karyogram
  hyperdiploidy, t(1;22)(p13;q13)/RBM15/MKL1 translocation, 36
  partial, acute leukemia, 24
  of peripheral blood lymphocyte, 91
  t(4;11)(q21;q23), 32
Karyotyping, 5–6
  ALK gene, 211
Kidney tumors. *See* Renal tumors
Knudson, A., 3, 16

L
Langer-Giedion syndrome, 155
LBL. *See* Lymphoblastic lymphomas (LBL)
Liver tumors. *See* Hepatoblastoma, biology of
Loss of hetrozygosity (LOH), 87, 90
Low-grade astrocytomas (LGA), 132
Low-grade fibromyxoid sarcoma (LGFMS)
  cAMP-responsive element-binding protein 3-like protein 2 *(CREB3L2)* gene, 209
  chromosomes 7 and 16, rearrangement t(7;16)(q33;p11.2), 208, 209
  cytology, 208
  fused in sarcoma *(FUS)* gene, 209
  hyalinizing spindle cell tumor with giant rosettes (HSTGR), 207, 208
Low-grade gliomas (LGG), 132
Luo, J.H., 250, 252
Lymphoblastic lymphomas (LBL), 112
Lymphoma
  aggressive NK-cell leukemia, 113
  anaplastic large cell lymphoma, 108–112
  array-based technologies, 118
  Burkitt lymphoma, 102–104
  diffuse large B-cell lymphoma, 104–107
  extranodal NK/T cell lymphoma, nasal type, 113
  follicular and marginal zone lymphomas, 114
  hepatosplenic gamma-delta T-cell lymphoma, 113
  Hodgkin lymphoma, 114–117
  lymphoblastic lymphomas (LBL), 112
  lymphoproliferative disorders, 113–114
  molecular diagnostic techniques
    pitfalls of, 117–118
    role of, 117
  non-Hodgkin lymphoma, 101–102
  primary mediastinal B-cell lymphoma, 107–108
Lymphoproliferative disorders (LPD), 113–114

M
Makishima, H., 87
Maris, J., 13
Matono, H., 204
Matrillin-2 expression, 135
Matrix metalloproteinase-7 (MMP-7), desmoid-type fibromatosis, 204
MDS. *See* Myelodysplasia (MDS)
Medulloblastomas, 126–132
  chromosome 17, 130, 131
  heterogeneity, 127–130
    anaplastic/large cell medulloblastomas, 127, 131
    development, 128
    with extensive nodularity, 127
    familial syndromes, 129
    histology, 128–129
    lower rhombic lip (LRL), 128
    molecular alterations, 129
    molecular features, 129–130
  high risk disease, criteria of, 126
  implications, patient management, 131
  metastatic stages, 126
  MYC/MYCN amplification, 130, 131
  PNETs, central and peripheral, 132
  Sonic Hedgehog pathway, 130
  subgroups of, 130–131
  upper rhombic lip (URL), 128
Merlin, 149
Mesenchymal chondrosarcoma, 162–163
Mesenchymal epithelial transition factor (MET) abnormalities, in osteosarcoma, 152
Metaphase G-banded karyotyping, myelodysplasia, 86
O6-Methylguanine-DNA methyltransferase (MGMT), 136
Microarray
  genome-wide analyses
    comparative genomic hybridization (CGH), 7
    epigenomics, 14
    expression profiling, 9–10
    microRNAs, 14
    proteomics, 15
    SNP arrays, 11
  profiling
    CGH, 63
    for leukemias classification, 65–66
    SNP, 63–64
    tumor suppressor genes, 63
Microarray innovations in leukemia (MILE study), 65–66
MicroRNAs, 14
Minimal residual disease (MRD) detection, 61–62
Mixed phenotype acute leukemia (MPAL), 23, 24
MLL gene, 31
Muller, H.J., 2, 16
Multiplex FISH (M-FISH), 56
Murine Double Minute 2 *(MDM2)* gene, 149
MYC translocation, Burkitt lymphoma, 102, 103
Myelodysplasia (MDS)
  in adult, 75
  apoptosis, 83
  bone marrow failure syndromes, with predisposition, 84
  chronic myelogenous leukemia, 75
  cytogenetic abnormalities, 83, 85
  definitions of, 81
  diagnosis of, 82–83
  genetic testing
    comparative genomic hybridization and SNP arrays, 87–90
    fluorescent in situ hybridization, 86–87
    metaphase G-banded karyotyping, 86
  megakaryocytic dyspoiesis, 83
  ringed sideroblasts, 82, 83
  uniparental disomy, 87
Myelodysplastic syndromes. *See* Juvenile myelomonocytic leukemia (JMML)

N
Nagata, T., 250
National Wilms Tumor Study Group (NWTS), 231–233
Neuroblastoma
  ALK gene, 174
  CD44 expression, 171
  differentiation, 170–171
  DNA ploidy tumor classification, 172
  ganglionic cell differentiation, 171
  gene amplifications, 172–174
  GWAS, 13
  histological features, 170
  NMYC amplification, 171–172
  prognosis, 173
  tyrosine kinase receptors, 175
Neurofibromatosis type 1 (NF1), 76
Neurofibromin 2 *(NF2)* gene, 149
NHL. *See* Non-Hodgkin lymphoma (NHL)
Nodular desmoplastic medulloblastomas, 130
Nodular lymphocyte predominant HL (NLPHL), 114

Non-Hodgkin lymphoma (NHL), 101–102
Noonan syndrome, 76, 77
Notch signaling, hepatoblastoma, 250
Nowell, P., 2, 6
Nucleophosmin *(NPM1)* mutations, acute myeloid leukemia, 35–36

O
Ohgaki, H., 136
Ordonez, N.G., 180
Osteoblastoma, 144–145
Osteochondroma, 154–156
Osteogenic tumors
  osteoblastoma
    clinicopathological characteristics, 144–145
    molecular pathology, 145
    nidus, 142, 143
  osteoid osteoma
    chromosomal abnormalities, 143
    clinicopathological characteristics, 142–143
    molecular pathology, 143–144
    nidus, 142
    YWHAB and PDGF-β genes, 144
  osteosarcoma
    histologic classification, 145–147
    molecular pathology, 148
Osteoid osteoma, 142–145
Osteosarcoma, 145–148
  cell cycle regulation abnormalities
    apoptosis mechanisms, 150
    RB1 pathway, 149–150
    SKP2, 151
    TP53 pathway, 148–149
    trastuzumab, 152
    URG4, 151
  chemotherapy resistance
    heat shock proteins (HSP), 154
    permeability glycoprotein (P-gp), 153
  histologic classification
    central (medullary) and surface (peripheral), 146
    chondroblastic, 147
    osteoblastic, 146
    telangiectatic, 147
  proto-oncogene abnormalities, 151–152
  telomere repair mechanisms, 153
  tyrosine-kinase receptor abnormalities, 152
  Wnt/β-catenin signaling pathway abnormalities, 153

P
Pardue, M.L., 6
Pediatric acute leukemia, evaluation
  clonal rearrangements, of IGH and TCR, 62–63
  comparative genomic hybridization, 57–59
  conventional G-banded karyotyping, 53–55
  fluorescent in-situ hybridization, 54–57
  microarray profiling, 63–66
  MRD detection, 61–62
  next generation sequencing, 66
  pharmacogenomics, 66
  polymerase chain reaction, 59–60
  rt-PCR assays, 61
Permeability glycoprotein (P-gp), in osteosarcoma, 153
Pharmacogenomics, for acute leukemia evaluation, 66
Philadelphia chromosome, 2, 28–31
Phosphatidylinositol-3'-kinase (PI3K)/AKT pathway, hepatoblastoma, 249
Pilocytic astrocytomas
  BRAF, 134, 135
  expansile compressive growth, 133
  HIPK2, 135
  MAPK pathway, activation of, 134
  Matrillin-2 expression, 135
PMBCL. *See* Primary mediastinal B-cell lymphoma (PMBCL)
Polymerase chain reaction (PCR), for chromosomal translocations diagnosis, 59–61
Primary mediastinal B-cell lymphoma (PMBCL)
  vs. classical Hodgkin lymphoma, 107–108
  IGH gene clonality assay, 108
  morphological and immunophenotypic features, 106
Primary renal synovial sarcomas (PRSS), 237–238
Primitive neuroectodermal tumors (PNETs), 175–179, 238
  medulloblastomas, 132
Proteomics, 15
Proto-oncogene abnormalities, in osteosarcoma
  c-Myc, 151
  Fos/Jun, 151–152
  MET, 152
PTPN11 gene, 77, 80

R
RAS signaling pathway, juvenile myelomonocytic leukemia, 76
Reed–Sternberg cells, 116
Refractory anemia with excess blasts (RAEB), 82
Refractory cytopenia, 82
Relling, M., 13
Renal cell carcinoma (RCC), 233–234
Renal tumors
in children and adolescents, 224
clear cell sarcoma of kidney (CCSK), 234–236
congenital mesoblastic nephroma (CMN), 237
desmoplastic small round cell tumor (DSRCTs), 238
diagnostic challenge, 223
fusion transcripts, 236
incidence, 223
primitive neuroectodermal tumors (PNET), 238
renal cell carcinoma (RCC)
histologic subtype and age group, 224
syndrome-associated, 234
translocation-associated, 234
rhabdoid tumor of kidney (RTK), 236
synovial sarcoma, 237–238
Wilms tumor, 225–233
Retinoblastoma (RB1) pathway abnormalities, in osteosarcoma, 149–150
Rhabdoid tumor of kidney (RTK), 223, 225, 236, 238
Rhabdomyosarcoma
alveolar
balanced translocations, 184–185
histologic criteria, 184
molecular alterations, 185
PAX3 and *PAX7*, 184–185
CDK4 protein, 187
diagnosis, 186–187
embryonal, 185
PAX3/FOXO1 fusions, 186–187
prognosis, 187–188
therapeutic features, 188
Rosai, J., 179
Rosenthal fibers, astrocytomas, 132
Rowley, J., 2, 16

S
Sellheyer, K., 206
Shing, D.C., 179
Shiraki, M., 183
Single nucleotide polymorphism (SNP)
arrays, 87–90
genome-wide association study (GWAS), 11
pharmacogenomics, 13
for chromosomal aberrations diagnosis, 63, 64
tag SNPs, 5
Small round blue cell tumors
desmoplastic small round cell tumor, 179–182
Ewing sarcoma/primitive neuroectodermal tumor, 175–179
nested/lobular pattern, 170
neuroblastoma, 170–175
rhabdomyosarcoma, 183–188
Societe Internationale D'oncologie Pediatrique (SIOP), 231–233
Soft tissue tumors
dermatofibrosarcoma protuberans (DFSP), 205–207
desmoid-type fibromatosis, 202–204
Gardner fibroma, 201–202
giant cell fibroblastoma, 205–207
infantile/congenital fibrosarcoma, 99–201
inflammatory myofibroblastic tumor (IMT), 209–213
low-grade fibromyxoid sarcoma (LGFMS), 207–209
Sonic Hedgehog pathway, 130
hepatoblastoma, 250
Spectral karyotyping (SKY), 56, 58
S-phase kinase-associated protein 2 (SKP2) abnormalities, in osteosarcoma, 151
Subungual exostosis, 158–159
Synovial sarcoma (SS), 225, 237–238

T
T-cell acute lymphoblastic leukemia (T-ALL), 34, 35
T cell receptor (TCR) gene rearrangement, 62–63
Therapy-related myeloid neoplasms (t-MN), 40
Tomizawa, M., 249
Transient myeloproliferative disorder (TMD), Down syndrome, 89–92
Trisomies, ALL, 29
Trisomy 21, 91, 92
Tumor protein p53 gene (TP53) abnormalities, in osteosarcoma, 148–150
Tyrosine-kinase receptor (Trk), 175
abnormalities, in osteosarcoma, 152

U
Uniparental disomy (UPD), 87, 90
Up-regulated gene 4 *(URG4)* abnormalities, in osteosarcoma, 151

V
van Doorninck, A.J., 178

W
WAGR syndrome, 229
Watson, J., 4, 6
Webb, T.R., 174
Wehrli, B.M., 201
Williamson, 186
Wilms tumor (WT)
  clinical presentation, 225
  histology
    blastemal cells, 226
    cystic, 226
    focal/diffuse anaplasia, 226
    monophasic tumors, 225
    nephrogenic rests, 226
  molecular studies, 225
  recurrent genetic abnormalities
    abdominal ultrasound, recommendation for, 229–230
    Beckwith–Wiedemann syndrome (BWS), 226
    CTNNB1, 230
    family with sequence similarity 123B (FAM123B), WTX, 230
    genitourinary anomalies, 229
    isolated hemihypertrophy, 228
    non-overgrowth syndromes/ anomalies, 229
    overgrowth syndromes/ anomalies, 226
    1p and 16q, loss of heterozygosity, 230–231
    WAGR syndrome, 229
  staging and treatment
    correlation of stage and histology, to survival, 232
    NWTS, 231
    percutaneous needle biopsy, 233
    recommendations, 232–233
    SIOP, 232
    survival rates for, 233
Wilms' tumor suppressor gene *(WT1)*, 181
Wnt signaling pathway
  abnormalities, in osteosarcoma, 153
  hepatoblastoma, 247–248
World Health Organization (WHO) classification
  acute leukemia, 23, 24
  osteosarcoma, 145, 146